Transvaginal mesh kits were surgical mesh devices designed to treat pelvic floor disorders through vaginal implantation, but the Food and Drug Administration (FDA) completely banned these products from the U.S. market in 2019. This regulatory action, known as the FDA ruling, came after years of mounting evidence that many women experienced severe complications including mesh erosion, chronic pelvic pain, and organ perforation. There are several types of surgery used to treat pelvic organ prolapse, and the FDA decision affects just one approach—a transvaginal mesh procedure.
This content addresses women currently living with pelvic mesh implants, those considering treatment for pelvic organ prolapse or stress urinary incontinence, and healthcare providers seeking comprehensive information about this medical device category. Understanding why transvaginal mesh products were removed from the market helps patients make informed decisions about their care and recognize warning signs that require medical attention.
What is a transvaginal mesh kit? A transvaginal mesh kit is a medical device made of surgical mesh intended to permanently address pelvic floor disorders, specifically pelvic organ prolapse (POP) and stress urinary incontinence (SUI), by reinforcing the vaginal wall. The mesh is implanted into the patient’s body, where its biocompatibility and the biological response of the patient’s body are important factors in determining the risk of complications.
The FDA determined that manufacturers failed to provide sufficient safety data demonstrating these devices offered benefits over existing treatments. After reclassifying transvaginal mesh for prolapse repair as high-risk Class III devices, the agency ultimately ordered all remaining products off the market when companies could not provide reasonable assurance of safety and effectiveness.
For those seeking alternatives, options such as the bladder sling are available. A bladder sling is a surgical procedure used to treat stress urinary incontinence and can also be considered in some cases of pelvic organ prolapse.
Key outcomes from this article include understanding:
- The composition and intended function of transvaginal mesh kits
- Why the FDA banned these devices and what the regulatory timeline revealed
- Complications to monitor if you have mesh implants
- How to identify what type of mesh you have
- Safer treatment alternatives available today for pelvic floor disorders
Introduction to Pelvic Floor Disorders
Pelvic floor disorders are a group of conditions that affect millions of women, often impacting quality of life and daily functioning. These disorders occur when the pelvic floor—the network of muscles and ligaments supporting the pelvic organs such as the bladder, uterus, and rectum—becomes weakened or damaged. Common pelvic floor disorders include pelvic organ prolapse, where the pelvic organs descend and bulge into the vagina, and stress urinary incontinence, which involves involuntary leakage of urine during activities like coughing or exercising.
Pelvic organ prolapse and stress urinary incontinence can develop due to childbirth, aging, surgery, or other factors that strain or injure the pelvic muscles and connective tissue. As these conditions progress, women may experience symptoms such as pelvic pain, urinary incontinence, discomfort, and a sensation of pressure or bulging in the vaginal area.
To treat pelvic floor disorders, medical procedures have evolved over time. Surgical mesh devices, including transvaginal mesh, were once widely used for pelvic organ prolapse repair and to treat stress urinary incontinence. Transvaginal mesh surgery was initially seen as a breakthrough, offering a minimally invasive way to reinforce weakened vaginal walls and support prolapsed organs. However, many women experienced serious complications, including mesh erosion, chronic pelvic pain, and new or worsening urinary incontinence. These risks led the Food and Drug Administration (FDA) to ban transvaginal mesh products for pelvic organ prolapse repair, citing safety concerns and insufficient evidence of benefit over traditional treatments.
Despite the FDA ban, pelvic floor disorders remain a significant health issue for many women. It is essential for patients to understand the potential risks and benefits of available treatments, including surgical mesh devices, and to consult with qualified healthcare providers when considering options for pelvic organ prolapse repair or other pelvic floor procedures. Recognizing symptoms early and seeking expert care can help women manage these conditions safely and effectively.
Understanding Transvaginal Mesh Kits
Transvaginal mesh kits consisted of pre-packaged sets containing specifically shaped surgical mesh implants and specialized instruments for vaginal implantation. These mesh kits were designed for pop repair, providing permanent support for prolapsed organs by reinforcing the weakened vaginal wall. The primary function of these kits is repairing weakened or damaged tissue, supporting and reinforcing areas compromised by pelvic organ prolapse or similar conditions. Surgeons would make a small incision in the vagina and use trocars or specialized needles to pass mesh arms through pelvic ligaments and anchor points, creating a supportive “hammock” beneath the bladder, uterus, or rectum.
The procedure was performed transvaginally because this approach offered shorter operating time and faster recovery compared with traditional abdominal surgery. However, the vaginal route placed synthetic materials directly against the vaginal wall where the patient’s body would interact with this foreign material permanently.
Synthetic vs. Biological Mesh Materials
What material is pelvic mesh made of? Pelvic mesh is primarily made from either synthetic polymers (such as polypropylene or polyester) or biologic materials (sterilized bovine or porcine tissue). Polypropylene remains the dominant synthetic material due to its physical strength, while biologic meshes are designed to be absorbed by the body over time.
How do synthetic and biological mesh materials differ in performance? Synthetic mesh, particularly polypropylene, integrates with surrounding tissue through a foreign-body reaction where fibroblasts and collagen grow into the mesh pores. This creates permanent tensile strength but can also drive chronic inflammation, scarring, and mesh contraction that contributes to pain and erosion. Synthetic materials with macroporous structures (pores greater than 75 micrometers) allow better tissue integration and lower infection rates than microporous designs.
Biologic mesh functions differently. Derived from animal tissue—typically porcine dermis or bovine pericardium—these materials are processed to remove cells while preserving the collagen scaffold. How do biologic mesh materials differ from synthetic polymer mesh? Rather than remaining permanently, biologic meshes act as temporary scaffolds that the patient’s body gradually remodels and absorbs. This reduces chronic foreign-body inflammation and late-stage erosion risk but provides weaker long-term mechanical support. Clinical studies show higher prolapse recurrence rates with biologic mesh compared with synthetic materials, though the risk of mesh-specific complications is lower.
Evolution of Pelvic Mesh Design
How has the design of pelvic mesh evolved over time? Surgical mesh first gained widespread use in the 1950s for abdominal hernias repair. By the 1970s, surgeons began using mesh for pelvic organ prolapse repair through abdominal approaches like sacrocolpopexy. The 1990s brought significant changes when gynecologists adapted mesh technology for transvaginal procedures, attracted by the promise of shorter surgeries and recovery times.
The FDA cleared the first pelvic mesh device for stress urinary incontinence (midurethral sling) in 1996 under the 510(k) process, treating it as a moderate-risk Class II device. By 2002, the first transvaginal mesh products specifically for pelvic organ prolapse received FDA clearance through the same pathway. Between 2005 and 2008, manufacturers including Boston Scientific and American Medical Systems introduced comprehensive mesh kits with pre-shaped implants featuring multiple arms and specialized trocars for standardized placement.
These kits were heavily marketed to general gynecologists rather than just subspecialist urogynecologists, expanding the pool of surgeons performing transvaginal mesh surgery. This commercialization coincided with increasing reports of serious complications, setting the stage for regulatory intervention. After the FDA reclassified transvaginal mesh devices for pelvic organ prolapse as high-risk Class III devices, manufacturers were required to submit a premarket approval application to demonstrate safety and efficacy before these products could remain on the market.
FDA Regulation and Complete Market Ban
The FDA’s path from initial approval to complete prohibition reflects evolving understanding of mesh-related risks and the agency’s determination that these medical procedures carried unacceptable dangers.
2019 FDA Ban and Market Withdrawal
Why did the FDA ban transvaginal mesh kits? The FDA completely prohibited transvaginal mesh kits in the U.S. in 2019 because manufacturers failed to provide sufficient safety data. Prior to the ban, the FDA had issued safety warnings and reclassified the products as high-risk Class III devices due to severe complications like mesh erosion and organ perforation.
In practical terms, “insufficient safety data” meant that premarket approval applications submitted by manufacturers did not demonstrate that transvaginal mesh for treating POP provided meaningful benefits over native tissue repair when accounting for mesh-specific complications. The FDA determined that women could receive effective treatment through alternative medical procedures without accepting the elevated risks these devices presented.
The FDA ban specifically targeted transvaginal prolapse repair using mesh kits. Importantly, this ruling did not affect midurethral slings used to treat stress urinary incontinence or mesh used in transabdominal procedures like sacrocolpopexy. These distinctions matter because some mesh procedures remain appropriate treatment options under current regulations.
Timeline of FDA Safety Actions
How did the FDA’s Class III reclassification affect mesh regulations? The reclassification fundamentally changed what manufacturers needed to prove before marketing these products.
2008: FDA issued its first Public Health Notification after receiving over 1,000 adverse event reports documenting mesh erosion, chronic pain, infection, and organ perforation in women with surgical mesh devices.
2011: The FDA announced that serious complications with transvaginal mesh for POP were “not rare” and that there was no clear evidence of greater clinical benefit compared with traditional native tissue repairs. This safety communication marked a turning point in regulatory approach.
2012: FDA orders required manufacturers to conduct 522 postmarket surveillance studies evaluating safety and effectiveness. Many of these studies were delayed or incomplete.
2016: The FDA reclassified transvaginal mesh for POP from Class II (moderate risk) to Class III (high risk). This reclassification meant manufacturers needed to submit premarket approval applications with robust clinical trial data rather than relying on substantial equivalence to existing devices. The Class III designation imposed stricter manufacturing standards, enhanced labeling requirements, and mandatory postmarket surveillance.
2019: When remaining manufacturers failed to provide adequate premarket approval applications, the FDA issued final orders requiring immediate cessation of sales and distribution.
Complications and Risk Assessment
Common Transvaginal Mesh Complications:
- Bleeding: Unexplained bleeding occurring weeks to months post-surgery
- Pelvic pain: Chronic, ongoing pain in the pelvic region
- Painful intercourse: Severe discomfort during sexual activity
- Vaginal wall erosion: The mesh physically wearing through the vaginal tissue
What are the most common risks and complications of mesh? Beyond the four major categories above, many women experienced mesh exposure into adjacent pelvic organs including the bladder, urethra, and rectum. Complication rates for vaginal mesh exposure after transvaginal POP mesh range from 5-15% in various clinical studies. Dyspareunia affects approximately 10-20% of patients in some series, with new-onset severe pain significantly impacting quality of life.
Other documented complications include urinary problems (retention, urgency, recurrent infections), mesh contraction causing vaginal shortening, nerve damage producing neuropathic pain syndromes, fistula formation creating abnormal connections between organs, and recurrent prolapse despite mesh placement.
Why did the FDA withdraw transvaginal mesh kits from the market? “Due to many reports of pain, erosion, infection, organ perforation, and bleeding, the FDA made the decision to withdraw transvaginal mesh kits from the market and reclassify them as high-risk Class III devices. This ultimately resulted in a complete prohibition in 2019.”
What is the controversy with pelvic mesh? “The use of surgical mesh to treat pelvic organ prolapse is associated with higher rates of complications, such as nerve damage and chronic pain, vaginal scarring and shrinkage, and even cases of organ perforation. Many women also experience problems such as mesh exposure erosion into the urinary tract or rubbing or becoming exposed in the vagina, which can lead to bleeding, discomfort, and painful intercourse.”
What were the initial benefits of transvaginal mesh kits? “Transvaginal mesh kits were first seen as a beneficial solution for pelvic organ prolapse and stress urinary incontinence, with advantages like reduced blood loss and shorter recovery periods when compared to traditional surgery.”
High-Level Summary (Key Takeaways): “The transvaginal mesh controversy arose due to reports of complications and led to the FDA’s safety warnings, reclassification as a high-risk device, and eventual market withdrawal in 2019. Alternative treatments for pelvic floor disorders include physical therapy, traditional surgical methods, and newer safer mesh products.”
Categorizing Mesh Materials: “Polypropylene: Because of its biocompatibility, physical strength, and simplicity of production, polypropylene (PP) remains the dominant material for transabdominal meshes.” “Biologic Materials: Meshes made from biological materials are constructed from the intestine or skin of animal tissue that has been sterilized and processed for use to treat pelvic organ prolapse. Usually, bovine (from cows) or porcine (from pigs) tissue is utilized to make animal mesh implants.”
FDA Regulations and Safety Reclassifications
The FDA reclassified transvaginal mesh for pelvic organ prolapse as a class III high-risk device in 2016. The FDA reclassified transvaginal mesh used for pelvic organ prolapse from a moderate-risk device to a high-risk device in January 2016. In 2016, the FDA reclassified transvaginal mesh used for pelvic organ prolapse from a moderate-risk device to a high-risk device. The FDA banned sales of all transvaginal mesh products for pelvic organ prolapse in April 2019. The FDA ordered all manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling their products in April 2019. The FDA did not place any restrictions on the use of mesh when the prolapse surgery is done through the abdomen.
Clinical Complications and Patient Care
Mesh erosion is the most common postoperative complication, affecting approximately 10.3% of patients within 12 months after pelvic organ prolapse repair. Postoperative pain is commonly experienced in the pelvic, groin, thigh region, or during sexual intercourse after transvaginal mesh surgery. Polypropylene mesh has been used for abdominal hernias since the 1950s. Transvaginal mesh was once used widely for nearly 25% of prolapse interventions until the FDA ban. Women who received transvaginal mesh for the surgical repair of pelvic organ prolapse should continue with their annual and other routine check-ups and follow-up care.
Legal Actions and Settlement Outcomes
Complications reported in lawsuits against the manufacturers of transvaginal mesh include bleeding, pain, inflammation, and infections. Legal actions against major transvaginal mesh manufacturers have resulted in significant settlements for women suffering from complications. Nearly $8 billion in settlements have been awarded to approximately 100,000 women in lawsuits related to transvaginal mesh complications.
Early Warning Signs and Symptoms
What are the earliest warning signs of severe transvaginal mesh complications? Patients should seek prompt evaluation if they experience:
- Persistent vaginal bleeding or discharge beyond expected postoperative healing, particularly weeks to months after surgery
- New onset pelvic pain that is increasing, radiates to the groin or thigh, or interferes with daily activities
- Painful intercourse or partner reporting feeling “prickling” or “sharp edges” during sexual activity
- Recurrent urinary tract infections or new difficulty urinating, urgency, or frequency
- Visible or palpable material protruding from the vaginal wall
- Fever or signs of infection such as severe pelvic tenderness
- Abnormal bowel symptoms including passage of gas or stool through the vagina
According to Mayo Clinic guidance on mesh complications, women experiencing any of these symptoms should see a urogynecologist or pelvic floor specialist familiar with mesh complications rather than assuming symptoms represent normal recovery.
Mesh Removal Challenges and Risks
Why is transvaginal mesh removal difficult? Complete transvaginal mesh removal is often impossible because the mesh is designed to permanently integrate with the surrounding tissue for long-term support. Attempting to remove it can exacerbate pain, cause excessive intraoperative bleeding, and result in organ damage.
Polypropylene mesh becomes densely incorporated into fibrous tissue over time. Mesh arms may pass through ligaments, pelvic muscles, and fascia, making dissection hazardous. Prior surgeries and chronic inflammation create dense adhesions that obscure anatomical planes. Surgeons often must remove mesh piecemeal, and small fragments may remain embedded, particularly if mesh has eroded into organs.
What are the risks and complications of mesh removal surgery? Mesh removal surgery can lead to severe injuries and complications, such as infection, bleeding, nerve damage, organ damage, colostomy, fistula formation, and the recurrence of hernias.
In the pelvic context, “hernia recurrence” translates to recurrence of prolapse or incontinence symptoms, sometimes more severe than before the original mesh implantation. Only specialized surgeons at tertiary urogynecology centers have adequate training for complex mesh excision procedures.
Material Identification for Existing Patients
How can a patient find out what material their pelvic mesh is made of? Several approaches help identify mesh composition:
- Request operative reports: Surgical notes should list the brand name, manufacturer, mesh type, and size implanted. Contact the hospital’s medical records department to obtain copies.
- Look for implant stickers: Many operations involve affixing product stickers with lot and reference numbers to the patient chart. These identify whether mesh is synthetic polypropylene, polyester, or biologic material.
- Contact the surgeon’s office: The operating surgeon can often recall or look up which products were standard at the time of surgery.
- Review pathology reports: If any mesh has been surgically removed and sent for analysis, pathology reports typically describe the material composition.
- Check for implant cards: Some institutions provide patients with cards documenting implanted device details, though this practice was not universal before increased regulatory scrutiny.
Treatment Alternatives and Safer Options
Alternatives to Transvaginal Mesh Kits: If you suffer from pelvic floor disorders, alternatives include:
- Nonsurgical options: Physical therapy (Kegels, squats) and the use of vaginal weights or pessaries
- Traditional surgical methods: Native tissue repair, laparoscopic, or robotic surgical interventions
- Bladder sling: Used to treat stress urinary incontinence and sometimes pelvic organ prolapse, a bladder sling supports the bladder and urethra to help prevent leakage.
- Newer mesh products: Safer, regulation-compliant transabdominal or self-cut mesh
Treatment selection depends on prolapse severity, patient age, desire for future vaginal intercourse, medical comorbidities, and individual preferences regarding conservative versus surgical management.
Nonsurgical Treatment Approaches
What are the nonsurgical physical therapy alternatives for pelvic disorders? Pelvic floor physical therapy represents first-line conservative treatment for many women with mild to moderate symptoms.
Pelvic floor muscle training includes supervised Kegel exercises with proper technique instruction, biofeedback using visual or auditory cues to teach correct muscle activation, and progressive resistance training. Contemporary rehabilitation programs incorporate functional movements like squats that integrate pelvic floor activation with whole-body strength development.
Vaginal weights or cones are devices held in place using pelvic floor contraction, with progressively increasing weight to build endurance and strength. Some programs use electrical stimulation to activate pelvic muscles when voluntary contraction proves difficult.
Pessaries are removable silicone devices inserted into the vagina to mechanically support prolapsed organs. According to Yale Medicine, pessaries offer a particularly valuable option for women wishing to avoid or delay surgery, including elderly or medically fragile patients. With periodic removal and cleaning, many women use pessaries successfully for years.
Lifestyle modifications complement these approaches: weight loss reduces intra-abdominal pressure on damaged tissue, constipation management prevents straining, and smoking cessation supports tissue healing.
Surgical Alternatives to Transvaginal Mesh
What are the safest pelvic mesh materials for prolapse surgery? For POP requiring mesh, transabdominal polypropylene mesh used in sacrocolpopexy is generally regarded as the best-studied, safest effective option available. This approach has been used safely for more than 30 years with good long-term success and favorable risk-benefit profile compared with transvaginal mesh.
Native tissue repair techniques use the patient’s own fascia and ligaments to reinforce or resuspend pelvic organs without foreign material. Procedures include anterior and posterior colporrhaphy and apical suspension with sutures anchored to sacrospinous or uterosacral ligaments. While some anatomical recurrence risk exists, avoiding mesh eliminates mesh-specific complications entirely.
Laparoscopic and robotic sacrocolpopexy combines mesh benefits with minimally invasive surgery. Small incisions, shorter recovery, and excellent long-term outcomes make this approach increasingly popular for apical prolapse support. The mesh is placed abdominally rather than transvaginally, using different tissue planes that result in lower complication rates.
Colpocleisis closes the vaginal canal and provides highly effective prolapse resolution without mesh for women who no longer desire vaginal intercourse.
Comparative data from systematic reviews show transvaginal synthetic mesh achieved better anatomical correction rates but at the cost of significantly higher reoperation rates for mesh-related complications. The regulatory consensus that emerged supports transabdominal mesh when indicated while native tissue repairs remain appropriate for many women.
Conclusion and Next Steps
The FDA’s decision to ban transvaginal mesh kits reflected accumulated evidence that these surgical mesh devices created unacceptable risks for many women without providing clear benefits over safer alternatives. Understanding this regulatory history helps current patients recognize that their symptoms deserve evaluation and that removal, while complex, may be appropriate.
If you have existing mesh implants:
- Obtain your surgical records to identify the specific device implanted
- Monitor for warning signs including unexplained bleeding, new pelvic pain, painful intercourse, or visible mesh exposure
- Seek evaluation from a urogynecologist experienced with mesh complications if symptoms develop
- Discuss removal options with specialists at tertiary centers if indicated
If you are seeking treatment for pelvic floor disorders:
- Request referral to a urogynecologist or pelvic floor specialist
- Explore conservative options including pelvic floor physical therapy and pessaries
- When surgery is appropriate, discuss native tissue repair and transabdominal mesh approaches with your surgeon
- Ask about surgeon experience and outcomes data for recommended procedures
Additional Resources
For comprehensive regulatory information, visit the FDA’s Urogynecologic Surgical Mesh Implants page.
The Mayo Clinic’s mesh information resource provides patient-oriented explanations of treatment options and risks.
Yale Medicine’s transvaginal mesh overview explains the 2019 ban context and surgical alternatives.
For background on mesh history and complications, Wikipedia’s transvaginal mesh article offers accessible overview information.
Clinical outcome data appears in the NCBI systematic review on transvaginal mesh efficacy.
Information about mesh removal surgery is available from CU Anschutz Urogynecology.
The American Urogynecologic Society (AUGS) provides clinical practice guidelines and patient education materials through their professional website.
